Compare BRCB & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | PYXS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.9M | 141.3M |
| IPO Year | N/A | 2021 |
| Metric | BRCB | PYXS |
|---|---|---|
| Price | $8.44 | $3.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $24.83 | $7.00 |
| AVG Volume (30 Days) | 261.7K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $30.74 | N/A |
| Revenue Next Year | $24.06 | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.11 | $0.97 |
| 52 Week High | $30.40 | $5.55 |
| Indicator | BRCB | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 62.85 |
| Support Level | $7.46 | $1.22 |
| Resistance Level | $8.70 | $3.40 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 58.08 | 84.22 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.